GRAIL to Present at 7th Annual Wolfe Research Healthcare Conference
Rhea-AI Summary
GRAIL (Nasdaq: GRAL) announced that company management will present at the 7th Annual Wolfe Research Healthcare Conference on Tuesday, Nov. 18, 2025 at 10:00 a.m. ET.
Live and replay webcasts will be available via the company's investor relations site at investors.grail.com, and the webcast will be archived and available for replay for at least 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction 3 Alerts
On the day this news was published, GRAL gained 4.90%, reflecting a moderate positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $141M to the company's valuation, bringing the market cap to $3.03B at that time.
Data tracked by StockTitan Argus on the day of publication.
Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-present-at-7th-annual-wolfe-research-healthcare-conference-302604500.html
SOURCE GRAIL, Inc.